- Markets
- Trading
- NOVARTIND
NOVARTIND
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Novartis India hits 24-year high on report of interest from Dr Reddy's
** Shares of Novartis India NOIN.BO rise as much as 10.9% to 1,148 rupees, highest since Feb. 7, 2000
** Shares surge after CNBC-TV18 reported on Saturday that Dr Reddy's REDY.NS plans to acquire Switzerland-based pharma co Novartis AG's NOVN.S stake in Novartis India
** It added that REDY's plans to acquire the domestic-focused portfolio and may offer controlling premium
** REDY's declined to comment; Novartis India did not immediately respond to Reuters request for comment
** Shares of REDY rise as much as 2.2% to a record high of 6,454 rupees
** More than 143,000 shares of NOIN change hands, 3.4x its 30-day avg
** NOIN eyes fifth straight session of gains and has risen ~15% so far in Feb.
(Reporting by Ashna Teresa Britto in Bengaluru)
(([email protected] ; ( +91 8078332441))
** Shares of Novartis India NOIN.BO rise as much as 10.9% to 1,148 rupees, highest since Feb. 7, 2000
** Shares surge after CNBC-TV18 reported on Saturday that Dr Reddy's REDY.NS plans to acquire Switzerland-based pharma co Novartis AG's NOVN.S stake in Novartis India
** It added that REDY's plans to acquire the domestic-focused portfolio and may offer controlling premium
** REDY's declined to comment; Novartis India did not immediately respond to Reuters request for comment
** Shares of REDY rise as much as 2.2% to a record high of 6,454 rupees
** More than 143,000 shares of NOIN change hands, 3.4x its 30-day avg
** NOIN eyes fifth straight session of gains and has risen ~15% so far in Feb.
(Reporting by Ashna Teresa Britto in Bengaluru)
(([email protected] ; ( +91 8078332441))
Novartis India Ltd Sept-Quarter Profit Rises
Oct 27 (Reuters) - Novartis India Ltd NOIN.NS:
NOVARTIS INDIA LTD SEPT-QUARTER PROFIT 236.8 MILLION RUPEES VERSUS PROFIT 183.5 MILLION RUPEES
NOVARTIS INDIA LTD SEPT-QUARTER REVENUE FROM OPERATIONS 787.6 MILLION RUPEES VERSUS 1.02 BILLION RUPEES
Source text for Eikon: ID:nBSE1Z4hyD
Further company coverage: NOIN.NS
(([email protected];))
Oct 27 (Reuters) - Novartis India Ltd NOIN.NS:
NOVARTIS INDIA LTD SEPT-QUARTER PROFIT 236.8 MILLION RUPEES VERSUS PROFIT 183.5 MILLION RUPEES
NOVARTIS INDIA LTD SEPT-QUARTER REVENUE FROM OPERATIONS 787.6 MILLION RUPEES VERSUS 1.02 BILLION RUPEES
Source text for Eikon: ID:nBSE1Z4hyD
Further company coverage: NOIN.NS
(([email protected];))
India drug regulator finds counterfeit medicines worth 20 mln rupees in raid
Aug 3 (Reuters) - India's drug regulator recovered counterfeit medicines worth more than 20 million rupees ($241,666) after a raid last month in the eastern city of Kolkata, the federal health ministry said on Thursday.
The raid, carried out by the Central Drugs Standard Control Organisation, found counterfeit copies of leading brands by manufacturers like Cipla CIPL.NS, Sun Pharma SUN.NS and Alkem Laboratories ALKE.NS, the health ministry said.
One person was arrested, it added.
"Further investigation to find the manufacturer and supply chain is ongoing to ensure supply of genuine medicine for consumption of general public," the health ministry said.
The medicines recovered included copies of acid reflux drugs like Pan-D and Pantocid DSR, manufactured by Alkem and Sun Pharma respectively, as well as Urimax-D, a medicine to treat an enlarged prostrate gland medicine, made by Cipla.
Authorities also recovered counterfeit copies of antibiotic medicines Augmentin and Clavam.
"Modi's government will not make any kind of compromise to stop adulterated medicines," health minister Mansukh Mandaviya said on Twitter, while congratulating the officers who carried out the raid.
The raid was the result of an investigation that began in January this year, following a complaint from Sun Pharma, when authorities recovered counterfeit medicines worth one million rupees ($12,083) the health ministry said.
($1 = 82.7590 Indian rupees)
(Reporting by Shilpa Jamkhandikar; editing by Christina Fincher)
(([email protected];))
Aug 3 (Reuters) - India's drug regulator recovered counterfeit medicines worth more than 20 million rupees ($241,666) after a raid last month in the eastern city of Kolkata, the federal health ministry said on Thursday.
The raid, carried out by the Central Drugs Standard Control Organisation, found counterfeit copies of leading brands by manufacturers like Cipla CIPL.NS, Sun Pharma SUN.NS and Alkem Laboratories ALKE.NS, the health ministry said.
One person was arrested, it added.
"Further investigation to find the manufacturer and supply chain is ongoing to ensure supply of genuine medicine for consumption of general public," the health ministry said.
The medicines recovered included copies of acid reflux drugs like Pan-D and Pantocid DSR, manufactured by Alkem and Sun Pharma respectively, as well as Urimax-D, a medicine to treat an enlarged prostrate gland medicine, made by Cipla.
Authorities also recovered counterfeit copies of antibiotic medicines Augmentin and Clavam.
"Modi's government will not make any kind of compromise to stop adulterated medicines," health minister Mansukh Mandaviya said on Twitter, while congratulating the officers who carried out the raid.
The raid was the result of an investigation that began in January this year, following a complaint from Sun Pharma, when authorities recovered counterfeit medicines worth one million rupees ($12,083) the health ministry said.
($1 = 82.7590 Indian rupees)
(Reporting by Shilpa Jamkhandikar; editing by Christina Fincher)
(([email protected];))
Novartis India June-Qtr Profit Drops
July 26 (Reuters) - Novartis India Ltd NOIN.NS:
JUNE-QUARTER PROFIT 202.6 MILLION RUPEES VERSUS 523.8 MILLION RUPEES
JUNE-QUARTER REVENUE FROM OPERATIONS 906 MILLION RUPEES VERSUS 1.21 BILLION RUPEES
Source text for Eikon: ID:nBSE8w0Hpq
Further company coverage: NOIN.NS
(([email protected];))
July 26 (Reuters) - Novartis India Ltd NOIN.NS:
JUNE-QUARTER PROFIT 202.6 MILLION RUPEES VERSUS 523.8 MILLION RUPEES
JUNE-QUARTER REVENUE FROM OPERATIONS 906 MILLION RUPEES VERSUS 1.21 BILLION RUPEES
Source text for Eikon: ID:nBSE8w0Hpq
Further company coverage: NOIN.NS
(([email protected];))
Novartis India swings to quarterly profit, shares up over 8%
** Shares of Novartis India Ltd NOIN.NS rise as much as 8.68% to 688.89 rupees; on track for fourth straight session of gains, if trend holds
** Pharma firm reports profit of 250.2 mln rupees ($3.1 mln) in March quarter, compared to a loss of 233.7 mln rupees a year earlier
** Approves one-time special dividend of 37.50 rupees per share and final dividend of 10 rupees per share
** Stock most active in nearly five months with a trading volume of 99,934 shares as of 10:15 a.m. IST, more than 10x the 30-day avg
** The relative strength index of the stock is 82, suggesting it may be overbought - Refinitiv data
($1 = 81.7800 Indian rupees)
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463))
** Shares of Novartis India Ltd NOIN.NS rise as much as 8.68% to 688.89 rupees; on track for fourth straight session of gains, if trend holds
** Pharma firm reports profit of 250.2 mln rupees ($3.1 mln) in March quarter, compared to a loss of 233.7 mln rupees a year earlier
** Approves one-time special dividend of 37.50 rupees per share and final dividend of 10 rupees per share
** Stock most active in nearly five months with a trading volume of 99,934 shares as of 10:15 a.m. IST, more than 10x the 30-day avg
** The relative strength index of the stock is 82, suggesting it may be overbought - Refinitiv data
($1 = 81.7800 Indian rupees)
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463))
Novartis India Reports Profit For March-Quarter
May 10 (Reuters) - Novartis India Ltd NOIN.NS:
MARCH-QUARTER PROFIT 250.2 MILLION RUPEES VERSUS LOSS 233.7 MILLION RUPEES
MARCH-QUARTER REVENUE FROM OPERATIONS 761.3 MILLION RUPEES VERSUS 983.2 MILLION RUPEES
Source text for Eikon: ID:nBSE9nSYN1
Further company coverage: NOIN.NS
(([email protected];))
May 10 (Reuters) - Novartis India Ltd NOIN.NS:
MARCH-QUARTER PROFIT 250.2 MILLION RUPEES VERSUS LOSS 233.7 MILLION RUPEES
MARCH-QUARTER REVENUE FROM OPERATIONS 761.3 MILLION RUPEES VERSUS 983.2 MILLION RUPEES
Source text for Eikon: ID:nBSE9nSYN1
Further company coverage: NOIN.NS
(([email protected];))
Upcoming Events:
Quarterly Results
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Novartis do?
Novartis India Limited operates in pharmaceuticals, generics, over the counter (OTC), and animal health segments. It provides prescription medicines, retail generic products, and products for cattle and poultry markets.
Who are the competitors of Novartis?
Novartis major competitors are Beta Drugs, Indoco Remedies, Syncom Formulations, Jagsonpal Pharma, Zota Health Care, Bliss GVS Pharma, Lincoln Pharma. Market Cap of Novartis is ₹2,073 Crs. While the median market cap of its peers are ₹1,677 Crs.
Is Novartis financially stable compared to its competitors?
Novartis seems to be less financially stable compared to its competitors. Altman Z score of Novartis is 2.2 and is ranked 8 out of its 8 competitors.
Does Novartis pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Novartis latest dividend payout ratio is 72.43% and 3yr average dividend payout ratio is 92.92%
How has Novartis allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Cash & Short Term Investments, Capital Work in Progress, Inventory, Accounts Receivable, Short Term Loans & Advances
How strong is Novartis balance sheet?
Balance sheet of Novartis is moderately strong.
Is the profitablity of Novartis improving?
The profit is oscillating. The profit of Novartis is ₹86.28 Crs for TTM, ₹85.19 Crs for Mar 2024 and ₹103 Crs for Mar 2023.
Is the debt of Novartis increasing or decreasing?
Yes, The debt of Novartis is increasing. Latest debt of Novartis is -₹597.24 Crs as of Sep-24. This is greater than Mar-24 when it was -₹1,192.14 Crs.
Is Novartis stock expensive?
Novartis is not expensive. Latest PE of Novartis is 24.03, while 3 year average PE is 44.76. Also latest EV/EBITDA of Novartis is 18.75 while 3yr average is 30.9.
Has the share price of Novartis grown faster than its competition?
Novartis has given lower returns compared to its competitors. Novartis has grown at ~3.52% over the last 7yrs while peers have grown at a median rate of 28.44%
Is the promoter bullish about Novartis?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Novartis is 70.68% and last quarter promoter holding is 70.68%.
Are mutual funds buying/selling Novartis?
There is Insufficient data to gauge this.